At the last check, the share price of the premier physician-led weight loss and metabolic health solutions company, ReShape Lifesciences Inc. (RSLS) was up 17.68% at $5.99 in pre-market trading on Friday. At the end of the last trading session, ReShape’s stock closed at $5.09, gaining 23.84 %. Prices ranged between $3.85 and $5.15 for RSLS stock.

RSLS stock traded 8.2 million shares, well above its average daily volume of 1.91 million shares over 100 days. Over the last five days, RSLS stock has gained 1.80%, while over the last month they have lost -49.20%. As a result of the company shifting its lead product manufacturing, RSLS stock has surged.

How has RSLS transitioned manufacturing?

As the nation’s leading company for weight loss and metabolic health, ReShape offers a complete line of proven products and services for the management of obesity and metabolic disease. In contrast to more invasive procedures such as gastric bypass or sleeve gastrectomy, the FDA-approved Lap-Band Program from RSLS offers its patients a minimally invasive, long-term treatment of obesity. Research (outside the U.S.) is being conducted with the ReShape Vest System, which mimics the gastric volume reduction effect of conventional weight-loss surgery by laparoscopically implanting a vest around the stomach.

With it, obese or morbidly obese patients can lose weight rapidly without altering their anatomy permanently. Reshapecare is RSLS’s weight-management program that helps patients lose weight quickly and maintain their weight loss over time. RSLS recently launched its online marketplace ReShape Marketplace to bring consumers quality wellness products targeted at achieving better health.

A Massachusetts manufacturer will now produce ReShape’s Lap-Bands after the company completed their transition from Apollo Endosurgery, Inc.

• In addition, RSLS expects to benefit from this change by reducing costs, bettering margins, and controlling the manufacturing process directly.
• A laparoscopic weight-loss device approved by the FDA specifically for people with BMIs of 30 or higher, the Lap-Band is now manufactured by RSLS.
• Since 1993, over one million patients have undergone this procedure and most insurance companies reimburse eligible patients for it.
• With 20 years of clinical evidence demonstrating lower complication and mortality rates than other surgical procedures, RSLS’ Lap-Band is proven to be the safest bariatric procedure available.

What will RSLS gain from the current decision?

ReShape (RSLS) will be in a better position to reduce cost and increase efficiency by bringing Lap-Band production under its direct operational control. RSLS has risen to meet the weight loss needs of a growing population and has also added manufacturing and logistics jobs to the United States since emerging from the recent pandemic.